IBD — a potential adverse effect of DDP4 inhibitors in T2DM
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Endocrinology"
DOI: 10.1038/s41574-018-0007-3
Abstract: Dipeptidyl peptidase 4 (DPP4) inhibitors are increasingly being used to treat patients with type 2 diabetes mellitus (T2DM); however, new research suggests that this class of drugs could increase the risk of incident inflammatory bowel… read more here.
Keywords: dpp4; effect ddp4; ibd potential; dpp4 inhibitors ... See more keywords